会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明授权
    • 한국형 C형 간염 바이러스의 특이항원인 KHCV 코아(CORE) 14 단백질의 정제방법
    • 韩国型HCV-CORE 14蛋白的纯化方法
    • KR1019930012111B1
    • 1993-12-24
    • KR1019910013598
    • 1991-08-06
    • 주식회사 엘지
    • 조중명임국진
    • C12N15/51
    • A recombinant strain Saccharomyces cerevisiae DC04-UB-CORE (ATCC 74081) carrying recombinant vector pYLBC-A/B-UB-CORE 14 was cultured in a leucine deficient medium containing 4 % glucose for 12 hrs at 30 deg.C. The preculture was inoculated to a YEPD medium containing 2 % glucose and culture for 24 hrs with shaking. The cell pellet was recovered by centrifugation and added with glass beads. After disruption of cell, insoluble precipitate was recovered by centrifugation. The insoluble precipitate was dissolved in a buffer containing 8 M urea and the specific antigen KHCV CORE 14 was purified from the solution by CM-Sepharose ion-exchange chromatography and S-200 gel filtration chromatography.
    • 携带重组载体pYLBC-A / B-UB-CORE14的重组菌Saccharomyces cerevisiae DC04-UB-CORE(ATCC 74081)在含有4%葡萄糖的亮氨酸缺乏培养基中在30℃下培养12小时。 将预培养物接种到含有2%葡萄糖的YEPD培养基中并振荡培养24小时。 通过离心回收细胞沉淀,并加入玻璃珠。 细胞破碎后,通过离心回收不溶性沉淀物。 将不溶性沉淀溶解在含有8M尿素的缓冲液中,通过CM-Sepharose离子交换层析和S-200凝胶过滤层析从溶液中纯化特异性抗原KHCV CORE14。
    • 6. 发明授权
    • 한국형C형간염진단시약및백신
    • 诊断试剂和疫苗用于KHCV
    • KR1019960015513B1
    • 1996-11-15
    • KR1019920010039
    • 1992-06-10
    • 주식회사 엘지
    • 조중명이용범박영우임국진최덕영소홍섭김천형김성택양재영
    • C12N15/51
    • The diagnostic agent and vaccine for korean hepatitis C virus(KHCV) is obtained by; (a) extracting RNA from the virus cell in the blood of a Korean C-type hepatitis patient; (b) subcloning cDNA form RNA; (c) expressing the protein in the eucaryotic cell such as yeast, animal or plant cell or procaryotic cell such as E.coli. The cDNA encodes KHCV, whose 842th amino acid is phenylalanine, 849th is leucine and 853th is threonine or 842th is leucine, 849th is phenylalanine and 853th is alanine. Using the more than 8 nucleotides corresponding to cDNA encoding KHCV, diagnostic kit or vacciue for KHCV is prepared.
    • 韩国丙型肝炎病毒(KHCV)的诊断剂和疫苗是通过以下方法获得的: (a)从韩国C型肝炎患者血液中的病毒细胞提取RNA; (b)将RNA亚克隆形成RNA; (c)在真核细胞如酵母,动物或植物细胞或原核细胞如大肠杆菌中表达蛋白质。 cDNA编码KHCV,其842位氨基酸为苯丙氨酸,第849位为亮氨酸,第853位为苏氨酸,第842位为亮氨酸,第849位为苯丙氨酸,第853位为丙氨酸。 使用对应于编码KHCV的cDNA的8个以上的核苷酸,制备用于KHCV的诊断试剂盒或试剂盒。
    • 9. 发明授权
    • 연어 성장 호르몬의 정제방법
    • 精炼生长激素的方法
    • KR1019940005595B1
    • 1994-06-21
    • KR1019910025503
    • 1991-12-30
    • 주식회사 엘지
    • 조중명임국진
    • C12N15/18
    • The method for purifying salmon growth hormone (SGH) comprises (a) culturing the recombinant E.coli (ATCC 68877) in which SGH is expressed in, (b) centrifuging it and crushing the obtained precipitate by ultrasonic wave, (c) selecting the insoluble protein in 50mM Tris buffer solution containing 2 mM EDTA, 5 mM beta mercaptoethanol and 4 M urea, (d) dissolving it with 6M guanidine and diluting it to be 1-3 M guanidine, (e) dissolving the precipitated protein in 5mM Tris buffer solution containing 2 % SDS, 5 mM DTT and 1 mM EDTA, and (f) executing S-200 resin chromatography and cephadex G-25 resin chromatography of the obtained material.
    • 纯化鲑鱼生长激素(SGH)的方法包括(a)培养重组大肠杆菌(ATCC 68877),其中SGH被表达,(b)离心并用超声波粉碎所获得的沉淀物,(c) 含有2mM EDTA,5mMβ巯基乙醇和4M尿素的50mM Tris缓冲溶液中的不溶性蛋白质,(d)用6M胍将其溶解并稀释至1-3M胍,(e)将沉淀的蛋白质溶于5mM Tris 含有2%SDS,5mM DTT和1mM EDTA的缓冲溶液,和(f)对所得材料进行S-200树脂色谱和cephadex G-25树脂色谱。
    • 10. 发明授权
    • 한국형 C형 감염 바이러스의 특이 항원인 KHCV MBP-코아(CORE) 17 단백질의 정제방법
    • 韩国型HCV核心蛋白的纯化方法
    • KR1019930012112B1
    • 1993-12-24
    • KR1019910013599
    • 1991-08-06
    • 주식회사 엘지
    • 조중명임국진
    • C12N15/51
    • A recombinant strain E. coli W3110 (ATCC 68639) carrying recombinant vector pMAL-KHCV 555 was cultured in a Luria medium containing ampicillin (50 μg/ml) for 12 hrs. The preculture was inoculated to Mg medium containing ampicillin (40 μg/ml), and cultured for 3-4 hrs with shaking. At OD650 = 0.4, IPTG (final conc. 0.1 mM) was added and cultured for 4 hrs with shaking. The cell pellet was recovered by centrifugation and treated with lysozyme and sonication. Insoluble precipitate was recovered by centrifugation and dissolved in a buffer containing 8M urea after treatment of Triton X-100 (1 %). The specific antigen KHCV MBP-CORE 17 was purified by Mono-S chromatography of FPLC.
    • 携带重组载体pMAL-KHCV555的重组菌株大肠杆菌W3110(ATCC 68639)在含氨苄青霉素(50μg/ ml)的Luria培养基中培养12小时。 将预培养物接种到含氨苄青霉素(40μg/ ml)的Mg培养基中,摇动培养3-4小时。 在OD 600 = 0.4时,加入IPTG(终浓度为0.1mM),摇动培养4小时。 通过离心回收细胞沉淀,并用溶菌酶和超声处理。 通过离心回收不溶性沉淀,处理Triton X-100(1%)后溶解在含有8M尿素的缓冲液中。 特异性抗原KHCV MBP-CORE 17通过FPLC的单色S色谱纯化。